At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 101 enrolled
Drug / intervention
Paclitaxel +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Paclitaxel, Carboplatin, and 3 other interventions for Triple-negative Breast Cancer. Completed, enrolled 101 participants across 9 sites.
Detailed Summary
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple-negative Breast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJul 2015
Primary CompletionFeb 2019
Study CompletionFeb 2020
TodayJul 2026
First PostedApr 9, 2015
Enrollment StartJul 1, 2015
Primary CompletionFeb 1, 2019
Study CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.2 years ago
Interventions
Paclitaxeldrug
Carboplatindrug
Doxorubicindrug
Cyclophosphamidedrug
Docetaxeldrug